Barclays lowered the firm’s price target on Amdocs (DOX) to $92 from $111 and keeps an Overweight rating on the shares. The views the company’s results “resilient”, with several wins in strategic domains. With the macro backdrop weighing on Amdocs’ end markets, investors will focus on the company’s double-digit earnings return policy, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOX:
- Amdocs FY26 Earnings Call: Solid Start, Cautious Outlook
- Amdocs price target lowered to $88 from $97 at Stifel
- Amdocs Posts Solid Q1 FY2026 Results, Expands Telco AI Push With T-Mobile Deal and aOS Launch
- Amdocs Names Shimie Hortig CEO as Shuky Sheffer Plans March 31 Retirement
- Amdocs price target lowered to $92 from $111 at Barclays